⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17874612 | 1.00 | — | — | |
| SCHEMBL17461994 | 1.00 | — | — | |
| SCHEMBL17147880 | 1.00 | — | — | |
| SCHEMBL14790170 | 1.00 | — | — | |
| SCHEMBL17462001 | 1.00 | — | — | |
| SCHEMBL17461992 | 0.82 | LMNA (0.33) | — | |
| SCHEMBL19321517 | 0.82 | LMNA (0.33) | — | |
| SCHEMBL13696846 | 0.82 | — | — | |
| SCHEMBL784380 | 0.82 | — | — | |
| SCHEMBL13250650 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238324-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2024-07-18 | — | — | US | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230331751-A1 | STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11707480-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230167151-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-01 | — | — | US | disclosed |
| US-11642361-B2 | Nucleoside phosphoramidate prodrugs | GILEAD SCIENCES, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
| US-10005811-B2 | β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8735372-B2 | Nucleoside phosphoramidate prodrugs | GILEAD PHARMASSET LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140045783-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC (US) | 2014-02-13 | — | — | US | disclosed |
| US-8580765-B2 | Nucleoside phosphoramidate prodrugs | GILEAD PHARMASSET LLC (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130029929-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | GILEAD PHARMASSET LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-8334270-B2 | Nucleoside phosphoramidate prodrugs | GILEAD PHARMASSET LLC (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110257122-A1 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS | PHARMASSET, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20100056770-A1 | PREPARATION OF NUCLEOSIDES RIBOFURANOSYL PYRIMIDINES | GILEAD PHARMASSET LLC | 2010-03-04 | — | — | US | disclosed |
| US-20080139802-A1 | Converting 2'-deoxy-2'-fluoro-2'-methyl-D-ribonolactones derivatives to 3-fluoro-3-methyl-2-chlorofuran compounds using chlorinating agent such as sulfuryl chloride, thionyl chloride or phosphorus oxychloride and tetrabutylammonium bromide | PHARMASSET, INC. | 2008-06-12 | — | — | US | disclosed |